{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:15:27Z","timestamp":1784934927697,"version":"3.55.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2024,11,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              The prevalence of invasive candidiasis caused by non-\n              <jats:italic>albicans Candida<\/jats:italic>\n              species is increasing.\n              <jats:italic>Candida guilliermondii<\/jats:italic>\n              is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              are sparse. Our study evaluated the antifungal susceptibility testing (AST) for\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              isolates submitted to a reference laboratory over a 12-year period (2012\u20132023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              fungemia. One hundred twelve blood culture isolates of\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8\u201320.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>\n              Our study addresses a significant knowledge gap in the clinical management of this non-\n              <jats:italic>Candida albicans<\/jats:italic>\n              species. Our retrospective review includes comprehensive AST data for 112\n              <jats:italic>Candida guilliermondii<\/jats:italic>\n              isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with\n              <jats:italic>C. guilliermondii<\/jats:italic>\n              fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/jcm.01057-24","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:43:14Z","timestamp":1729687394000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["<i>Candida guilliermondii<\/i>\n            fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-232X","authenticated-orcid":true,"given":"Jack W.","family":"McHugh","sequence":"first","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Bayless","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-6214","authenticated-orcid":true,"given":"Nischal","family":"Ranganath","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton R.","family":"Kind","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-8219","authenticated-orcid":false,"given":"Nancy L.","family":"Wengenack","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya S.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5363-x"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.26"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.08.081"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101215"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01960.x"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02117-09"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2022.2123325"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01889-08"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02615-20"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/femsyr\/foz037"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myaa005"},{"key":"e_1_3_1_13_2","volume-title":"CLSI supplement M27M44S","author":"Clinical and Laboratory Standards Institute U","year":"2022","unstructured":"Clinical and Laboratory Standards Institute U. 2022. Performance standards for antifungal susceptibility testing of yeasts. In CLSI supplement M27M44S"},{"key":"e_1_3_1_14_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2023. Overview of antifungal ECOFFs and clinical breakpoints for yeasts moulds and dermatophytes using the EUCAST E.Def 7.4 E.Def 9.4 and E.Def 11.0 procedures. Available from: http:\/\/www.eucast.org. Retrieved 08 Nov 2023."},{"key":"e_1_3_1_15_2","volume-title":"CLSI supplement M57S","author":"Clinical and Laboratory Standards Institute U","year":"2022","unstructured":"Clinical and Laboratory Standards Institute U. 2022. Epidemiological cutoff values for antifungal susceptibility testing. In CLSI supplement M57S"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.2.622-626.2004"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myy038"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05115-22"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.3.591-595.1999"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02261-19"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.05.008"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00069-19"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00865-06"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00938-16"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40280-8"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02644-16"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02481-13"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-17"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01057-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01057-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T14:01:58Z","timestamp":1731506518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01057-24"}},"subtitle":[],"editor":[{"given":"Tanis C.","family":"Dingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,13]]}},"alternative-id":["10.1128\/jcm.01057-24"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01057-24","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"2024-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01057-24"}}